Professor Richard Price
Curing Plasmodium vivax malaria
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Professor of Tropical Medicine
- Wellcome Clinical Fellow, Asia Pacific, Australia
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with 15 malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- define the direct and indirect morbidity and mortality of vivax malaria
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria,
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN) and co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
- Clinical trials of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Ex vivo drug susceptibility of novel antimalarial compounds
Timika, Papua, Indonesia
Sumatra Site for IMPROV Study
Ex vivo Lab
Das D. et al, (2022), Malaria Journal, 21
Mansoor R. et al, (2022), BMC Medicine, 20
Huwe T. et al, (2022), Malaria Journal, 21
Dahal P. et al, (2022), Malaria Journal, 21
Duffy MF. et al, (2022), Nat Commun, 13
Stepniewska K. et al, (2022), BMC Medicine, 20